Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients
试验速览
- 阶段
- 4 期
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Changes of bone mineral density
研究概览
简要总结
It has not been well known about the changes of bone metabolic markers, bone mineral density and other bone-related markers after teriparatide and/or denosumab treatment in Japanese osteoporotic patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 120 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Osteoporotic patients
排除标准
- 未提供
研究组 & 干预措施
Denosumab and/or teriparatide treatment
Denosumab and/or teriparatide treatment in osteoporotic patients
干预措施: Denosumab treatment in osteoporotic patients (Drug)
Denosumab and/or teriparatide treatment
Denosumab and/or teriparatide treatment in osteoporotic patients
干预措施: Teriparatide treatment in osteoporotic patients (Drug)
Denosumab and/or teriparatide treatment
Denosumab and/or teriparatide treatment in osteoporotic patients
干预措施: Denosumab and teriparatide treatment in osteoporotic patients (Drug)
结局指标
主要结局
Changes of bone mineral density
时间窗: every 4-6 months
Bone mineral density will be examined every 4-6 months to evaluate the suitability of the drug.
次要结局
- Changes of bone turnover markers(every 3-6 months)
研究者
Yukio Nakamura
Assistant Professor
Shinshu University